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Autism spectrum disorders (ASD) are characterized by impairments in communication, social interactions, and repetitive
behaviors. While the etiology of ASD is complex and likely involves the interplay of genetic and environmental factors, growing
evidence suggests that immune dysfunction and the presence of autoimmune responses including autoantibodies may play a role
in ASD. Anti-phospholipid antibodies are believed to occur from both genetic and environmental factors and have been linked
to a number of neuropsychiatric symptoms such as cognitive impairments, anxiety, and repetitive behaviors. In the current study,
we investigated whether there were elevated levels of anti-phospholipid antibodies in a cross-sectional analysis of plasma of young
children with ASD compared to age-matched typically developing (TD) controls and children with developmental delays (DD)
other than ASD. We found that levels of anti-cardiolipin, 𝛽2-glycoprotein 1, and anti-phosphoserine antibodies were elevated in
children with ASD compared with age-matched TD and DD controls. Further, the increase in antibody levels was associated with
more impaired behaviors reported by parents. This study provides the first evidence for elevated production of anti-phospholipid
antibodies in young children with ASD and provides a unique avenue for future research into determining possible pathogenic
mechanisms that may underlie some cases of ASD.
1. Introduction
Autism spectrum disorders (ASD) are a group of neurode-
velopmental disorders characterized by stereotyped interests,
repetitive behaviors, and impairments in communication
and social interaction. Currently 1 in 88 children has been
identified as having ASD [1]. Despite the high incidence of
ASD, etiology and pathogenesis remain poorly understood.
Current research suggests a significant role for immunodys-
regulation and autoimmuneprocesses in the pathophysiology
of ASD, with the existence of autoantibodies directed against
neuronal proteins repeatedly demonstrable in a substantial
number of children with ASD (reviewed in [2, 3]).
The reported targets of autoantibodies exhibited by chil-
dren and adults with ASD are diverse and range from
neurotransmitter receptors such as serotonin receptors,
markers of astroglial activation such as glial fibrillary acidic
protein (GFAP), and myelin sheath cellular products such
as myelin basic protein (MBP), as well as yet unidentified
neuronal protein targets (reviewed in [4]). Moreover, the
presence of neuronal protein-specific autoantibodies are
associated with increased behavioral impairments and more
severity in children with ASD [5], suggesting a link between
the autoimmune processes and behavioral dysfunction. For
example, autoantibodies directed against a 45 kDa protein
present in the cerebellum were not only found more fre-
quently in children with ASD but were also associated
with lower adaptive and cognitive function, as well as
increased aberrant behaviors [6, 7]. However, replication
studies of antibody-specific antigen targets, such as MBP
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and GFAP, have been inconsistent, suggesting that further
studies are needed to identify the target or targets and/or
associated autoimmune phenomena [8, 9]. Recent studies
have highlighted a role for anti-phospholipid antibodies in
altering function and behaviors such as cognition, anxiety,
and hyperactivity.
Anti-phospholipid antibodies recognize a number of
diverse targets including cardiolipin, phosphoserine, and 𝛽2-
glycoprotein 1. They are found in roughly ten percent of
the population [10, 11] but are thought to cause pathology
in only a small segment of those with antibodies. Elevated
levels of anti-phospholipid antibodies have been found in the
blood and cerebral spinal fluid of psychiatric patients having
hallucinatory and/or delusionary episodes [12]. In individ-
uals with neuropsychiatric systemic lupus erythematosus,
elevated titers of anti-cardiolipin antibodies are reported
most often in patients with cognitive impairment, psychosis,
depression, seizures, chorea, and migraines [13]. Moreover,
in animal models, administration of anti-phospholipid anti-
bodies to rodents can induce a number of psychological side
effects, including increased anxiety and decreased cognition
learning and memory [14, 15].
When anti-phospholipid antibodies are present in an
individual consistently over time, along with arterial or
venous thrombosis or pregnancy morbidity, this is termed
antiphospholipid syndrome (APS). Although rare in chil-
dren, APS does occur and is thought to be underdiagnosed
likely due to lack of testing in this population, as these autoan-
tibodies are generally related to fertility and cardiovascular
events [16]. It is still unclear what the presence of elevated
levels of anti-phospholipid antibodies signify in the pediatric
population in terms of comorbidities [17].
Based on the links between anti-phospholipid antibodies
and altered behaviors and cognition, we evaluated a panel
of autoantibodies associated with APS including anticar-
diolipin, antiphosphoserine, and anti-𝛽2-glycoprotein 1 in
plasma from a large cohort of well-characterized children
enrolled in a population-based case-control study. To better
define the immune status of children with ASD, autoantibody
profiles were assessed in children 24–82 months of age who
had ASD and compared with typically developing children
and children with developmental delays other than ASDwho
were of the same age and lived in the same geographical area.
In addition, antibody levels were investigated for associations
with clinical behavioral outcomes.
2. Methods
2.1. Subjects. One hundred and nine participants who
were enrolled through the population-based case controlled
Childhood Autism Risks from Genetics and Environment
(CHARGE) study conducted at UC Davis MIND Insti-
tute were recruited to this study [18]. The study protocols
including recruitment and behavioral assessments have been
described in detail [18–20]. In brief, following clinical evalua-
tion for diagnostic confirmation, participants were placed in
one of three groups: (1) children with a confirmed diagnosis
of ASD [𝑁 = 54, median age 44.8 months (interquartile
range 32.0–57.7), 45 males]; (2) children diagnosed with
developmental delay but not ASD [𝑁 = 22. median age 41.7
months (IQR 25.7–57.8), 18 males.]; or (3) children who
were confirmed as typically developing controls [𝑁 = 33,
median age 40.6 months (IQR 27.7–53.6), 27 males]. Final
diagnosis of ASD was confirmed by the Autism Diagnostic
Interview-Revised (ADI-R) [21] and the Autism Diagnostic
Observation Schedule (ADOS) [22]. The ADOS and ADI-
R consist of a standardized, semistructured interview and
a diagnostic algorithm from the Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition Text Revision
(DSM-IVTR) [23], with definitions of autism from the Inter-
national Classification of Diseases, Tenth Revision (ICD-10)
[24]. The administration of all diagnostic instruments was
carried out by experienced clinicians at the UC Davis MIND
Institute.
Additional behavior testing included theAberrant Behav-
ior Checklist (ABC), Mullen Scales of Early Learning
(MSEL), and Vineland Adaptive Behavior Scales (VABS).
The ABC was taken by parents of children in the study and
consists of questions designed to measure the severity of
autism-associated behaviors, including irritability, lethargy,
stereotypy, hyperactivity, and inappropriate speech. Assess-
ment scores for the ABC range from 0 to 174, with higher
scores indicatingmore severely affected behavior. In addition
to the ABC, children enrolled in the study were assessed for
cognitive function using MSEL. The MSEL has components
for visual reception, fine motor, receptive language, and
expressive language, each of which yields a 𝑇 score with
mean = 50 and SD = 10. Adaptive function was assessed
through parental interview using the VABS. The VABS has
components for communication, daily living, socialization,
andmotor skills.These components each component yields a
score from 20 to 160 with a mean among typically developing
children of 100.
Participants did not differ for age or sex ratios. All chil-
dren were medication-free and in good health and without
diagnosis of autoimmune conditions at time of the blood
draw. This study was approved by the institutional review
boards in the University of California, Davis. Informed
consent was obtained prior to participation.
2.2. Antibody Analysis. For each subject peripheral blood
was collected in acid-citrate-dextrose Vacutainers (BD Bio-
sciences; San Jose, CA), centrifuged at 2300 rpm for 10min
and the plasma harvested. Plasma was aliquoted and stored
at −80∘C until antibody levels were measured. The IgG
antibody levels of anticardiolipin, antiphosphoserine, and
anti-𝛽2-glycoprotein 1 were assessed by commercial ELISA
(Orgentec, Mainz, Germany) using the manufactures pro-
tocol. In brief, plasma samples were diluted 1 : 100 in assay
buffer, and 100 uL of diluted plasma was loaded on plate
in duplicate along with calibrators and controls. Samples
were incubated for 30 minutes at room temperature. Sam-
ples were visualized using 3,3󸀠,5,5󸀠-tetramethylbenzidine
(TMB) substrate and read at 450 nm. All results are
reported in IgG phospholipid units per milliliter (GPL-U/
mL).
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Figure 1: Anti-phospholipid antibody levels. (a) ASD subjects were found to have significant (𝑃 < 0.01) levels of anti-phosphoserine and (b)
anti-𝛽2-glycoprotein 1 antibodies comparedwith TD andDD controls. Levels of (c) anti-cardiolipin were found to be significantly (𝑃 < 0.001)
higher in ASD compared with TD control, but differences to DD control did not reach significance. ∗𝑃 < 0.01, and ∗∗𝑃 < 0.001.
2.3. Statistical Analysis. Data analysis was performed using
STATA 12 software. Data was determined as nonparametric
using Shapiro-Wilks test for normality. Wilcoxon rank-sum
tests were used to compare antibody levels between sub-
ject groups. Spearman correlations were used to determine
the association between anti-phospholipid antibodies and
variations in scores on behavioral, cognitive, and adaptive
assessments. A probability value (𝑃) of less than 0.05 was
considered to be significant.
3. Results
3.1. Anti-Phospholipid Antibody Levels in ASD. An approx-
imate 38% increase in anti-phosphoserine antibody levels
were observed in children with ASD compared with TD
controls (mean 3.209 ± SEM 0.204 versus mean 2.324 ± SEM
0.149; 𝑃 < 0.01) and a 37% increase compared with children
with DD (mean 3.209 ± SEM 0.238 versus mean 2.344 ± SEM
0.172; 𝑃 < 0.01) (Figure 1). There was also a 149% increase in
anti-𝛽2-glycoprotein 1 antibody levels in children with ASD
comparedwith age-matched TD controls (mean 4.584± SEM
0.294 versus mean 1.845 ± SEM 0.224; 𝑃 < 0.001) and a 132%
increase over children with DD (mean 4.584 ± SEM 0.294
versus mean 1.975 ± SEM 0.406; 𝑃 < 0.001). Antibody levels
of anticardiolipin were increased approximately 75% higher
in children with ASD compared with TD controls (mean
2.873± SEM0.245 versusmean 1.642± SEM0.121;𝑃 < 0.001),
and there was a trend toward elevated levels in children with
ASD compared with DD controls, although this did not reach
statistical significance after multiple comparison correction
(Figure 1).
3.2. Association of Anti-Phospholipid Antibody Levels and
Behaviors. We next examined whether anti-phospholipid
antibody levels were associated with impairments in behav-
ior. Significant associations were found between all three
anti-phospholipid antibodies assessed and increased severity
of behaviors, such as lethargy, irritability, and stereotypic
behaviors as assessed by the ABC. Impairments in cognitive
and adaptive behaviors as measured by MSEL and VABS
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Table 1: Association analysis of anticardiolipin, 𝛽2-glycoprotein 1, and antiphosphoserine with behavioral outcome measures as assessed
by the Aberrant Behavior Checklist (ABC), Mullen Scales of Early Learning (MSEL), and Vineland Adaptive Behavior Scales (VABS) using
Spearman’s rank correlations demonstrated that there were significant correlations between anti-phospholipid antibody levels and the severity
of impairments in behavior in participants enrolled in this study. For the ABC, a higher score corresponds to more behavioral impairments.
For the MSEL and VABS, a lower score corresponds to increased cognitive and adaptive impairments.
Autoantibody profile Cardiolipin 𝛽2-Glycoprotein 1 Phosphoserine
𝑃 value 𝑟 𝑃 value 𝑟 𝑃 value 𝑟
Aberrant Behavior Checklist
Subscale I: irritability <0.001 0.368 0.001 0.343 0.002 0.312
Subscale II: lethargy 0.001 0.334 <0.001 0.406 0.001 0.317
Subscale III: stereotypy 0.002 0.309 <0.001 0.421 0.002 0.309
Subscale IV: hyperactivity 0.010 0.257 0.001 0.343 0.040 0.206
Subscale V: inappropriate speech 0.409 0.084 0.010 0.258 0.865 0.017
Subscale VI: moods <0.001 0.345 <0.001 0.346 0.002 0.303
Mullen Scales of Early Learning
Visual reception 0.031 −0.206 0.002 −0.291 0.042 −0.195
Fine motor 0.004 −0.272 0.002 −0.292 0.002 −0.300
Receptive language 0.009 −0.249 <0.001 −0.356 0.003 −0.286
Expressive language 0.004 −0.271 <0.001 −0.350 0.007 −0.257
Vineland Adaptive Behavior Scales
Communication 0.011 −0.244 0.003 −0.284 0.001 −0.324
Daily living skills 0.047 −0.190 0.007 −0.255 0.014 −0.234
Socialization 0.022 −0.219 0.002 −0.289 0.002 −0.287
Motor skills 0.088 −0.164 0.127 −0.147 0.014 −0.236
were also associated with increased antibody levels. These
impairments included deficits in functional communication
on the VABS and receptive and expressive language domains
measured by the MSEL (Table 1). Although there were strong
correlations observed in the pediatric population as a whole,
there were no significant differences found when analyzing
within the individual groups based on diagnosis.
4. Discussion
In this study we demonstrate that the levels of anti-
phospholipid antibodies in children with ASD are signif-
icantly elevated when compared with typically developing
children and children with developmental delays other than
ASD. Furthermore, elevated anti-phospholipid antibodies
are associated with increased impairments in a number of
clinical cognitive and behavioral measures such as stereotypy,
hyperactivity, and communication. Together with previous
studies in the field demonstrating the increased presence of
autoantibodies in children with ASD, this study adds further
support for a possible role for autoimmune phenomena
in the pathogenesis of ASD [25]. Several previous studies
have shown that increased anti-phospholipid antibodies are
present in a number of neuropsychiatric conditions; however,
it is currently unclear what, if any, pathologic significance
these anti-phospholipid antibodies have in behavioral disor-
ders including ASD. In addition, it is noteworthy that while
this study found elevated anti-phospholipid antibodies in
children with ASD, the levels are below what is considered
clinically significant levels for APS. These current data high-
light the importance for further research to investigate the
role of anti-phospholipid antibodies in a variety of childhood
behavioral disorders.
APS in children is thought to be rare; however, current
assessments are biased away from recognizing the syndrome
in prepubescent individuals [17]. One study demonstrated
that anti-phospholipid autoantibody levels are elevated in
a significant number of children, suggesting that elevated
levels of anti-phospholipid antibodies may have importance
in children even in the absence of the defining clinical features
of APS, such as arterial or venous thrombosis or pregnancy
morbidity that is observed in adults [26]. The additional
symptoms of APS vary greatly in adults, with cognitive [27],
neuropsychiatric [12, 13], and neuromotor [28] symptoms
having been observed. Animal models of APS, in which
antibodies isolated from individuals with APS are transferred
into mice, demonstrate that the effects of the antibodies are
associated with neuropsychiatric symptoms such as anxiety,
hyperactivity, and impairments in cognition [15, 29, 30].
Anti-phospholipid antibodies have been associated with
numerous central nervous system involvements, with many
symptoms such as stroke and optic neuropathy thought to
result from thrombic events. However, the exact mecha-
nism of how these antibodies cause pathology is unknown
(reviewed in [31, 32]). It is unlikely that the thrombotic
events are responsible for all APS-related symptoms; in many
subjects with chorea, lesions are not apparent on CT scans,
suggesting that a more direct cellular mechanism could be
involved [25, 33, 34]. Direct binding of anti-phospholipid
Mediators of Inflammation 5
antibodies to neurons has been demonstrated in human
neurons ex vivo, and these antibodies have been shown to
permeabilize and depolarize brain synaptoneurosomes [35,
36]. In mice, when anti-phospholipid antibodies derived
from human subjects are administered they recognize neu-
ronal targets and have been shown to decrease astroglia
proliferation [37]. It is not clear how this could translate
to pathology in ASD, but many studies have shown the
increased presence of autoantibodies that interact with neu-
ronal targets. The exact targets are generally not known in
ASD, but it is possible that these antibodies, or at least a
fraction, could be anti-phospholipid antibodies [7, 25, 34]. In
addition, anti-phospholipidsmay be related to other previous
findings such asMBP-specific antibodies [5]. In subjects with
SLE increased, elevated anti-cardiolipin antibodies titers are
associated with increased myelin binding antibodies [38].
Alternatively, anti-phospholipid antibodies may repre-
sent a biomarker for nonspecific neuronal damage or inflam-
mation. In a study looking at anti-neuronal antibodies in
129 young children with and without ASD, 43% of children
showed some positive staining for brain reactive antibodies
[38]. Although a differential pattern of staining was not read-
ily apparent between those childrenwithASD comparedwith
controls, those children who did show positive autoantibody
staining displayed more severe score on the Child Behavior
Checklist (CBCL) [39]. This suggests that non-specific anti-
brain antibodies may hearken a more general developmental
impairment. In fact, in ASD numerous antibodies directed
against brain or central nervous system tissue have been
identified (reviewed in [2]). The targets of these antibodies
are quite diverse and include serotonin receptors [40], MBP
[41], nucleus [42], and GFAP [43], as well as numerous
unidentified protein targets. Moreover, unique autoantibody
targets seem to be found only in subsets of children with
ASD, and their detection has been difficult to replicate across
studies; primary examples are antibodies against such targets
as MBP and GFAP [8, 9]. Additionally, anti-phospholipid
antibodies have been associated with a number of infectious
agents, such as syphilis or HIV [44, 45]. However, there is
no evidence of increased rates of infection in children with
ASD at the ages reported in this study, and all participants
in the study were screened for illness at the time of the blood
draw [46, 47]. Given the apparent ability of anti-phospholipid
antibodies to discriminate children with ASD compared
with controls as seen in this study, these antibodies may
offer additional novel biomarkers for evaluating pathogenic
mechanisms and possible targeted treatments for children
with ASD.
While this study is limited due to its cross-sectional
nature and further longitudinal testing is warranted, it is
among the first to attempt tomeasure anti-phospholipid anti-
bodies in a pediatric population with ASD with age-matched
controls. The associations between anti-phospholipid anti-
body levels and impairments in behaviors may be of sig-
nificance to young children beyond those with ASD. In
particular, we demonstrate that these autoantibodies are
associated with impairments in behaviors similar to previous
studies looking at unidentified neuronal targets [7]. These
observations warrant further study.
5. Conclusion
In summary, the findings of increased anti-phospholipid
antibody levels in young children with ASD, and the asso-
ciation between antibody levels and impaired behaviors in
the pediatric population as a whole, offer potential new
targets for understanding the mechanisms involved in the
pathogenicity of ASD. Our novel preliminary findings sup-
port the importance of further study of the biological impact
of autoantibodies and their association with behavioral and
cognitive impairments in children with ASD.
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